Oral ulcerations are associated with the loss of response to infliximab in Crohn's disease

Journal of Oral Pathology and Medicine

Volumn 34, Issue 1, 2005, Pages 53-55

  Sánchez, Andrés R ^a   Rogers III, R S ^a   Sheridan, P J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anti tumor necrosis factor therapies; Antibodies to infliximab; Crohn's disease; Infliximab

Indexed keywords

ADALIMUMAB; DAPSONE; DRUG ANTIBODY; INFLIXIMAB; MERCAPTOPURINE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; CROHN DISEASE; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGUS ULCER; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; MALE; MOUTH ULCER; PRIORITY JOURNAL; RECURRENT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DERMATOLOGIC AGENTS; DRUG TOLERANCE; ESOPHAGEAL DISEASES; HUMANS; MALE; ORAL ULCER; ULCER;

EID: 12444314980     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2004.00273.x     Document Type: Article

References (5)

1. Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res 2003; 47: 1-10.
2. Ricard E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722-9.
3. Agnholt J, Dahlerup JF, Buntzen S, Tottrup A, Nielsen SL, Lundorf E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Aliment Pharmacol Ther 2003; 17: 703-10.
4. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24.
5. Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 2003; 124: 1140-5.